An interventional study of 5-session UP condition and 8-session UP condition in Emotional Disorder, Anxiety Disorders and Depressive Disorder, sponsored by Instituto de Investigación Sanitaria Aragón. Recruiting at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Instituto de Investigación Sanitaria Aragón · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies in Anxiety Disorders with a site in Spain — 58 open to participants now, 68 under way, 2 of them phase 3. Anxiety Disorders · Spain.
Among the 230 studies in Anxiety Disorders with a site in Spain, this one is the 44th largest by planned enrollment of the 198 interventional ones that give a count, is one of 20 that started in 2026, is one of 181 with no phase, reaches primary completion later than 52 of the 67 other live ones, and was the 165th registered.
7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.
Browse Anxiety Disorders studies →58 of the 230 studies in Anxiety Disorders with a site in Spain are open now. Recruiting first, the newest first:
Hospital Miguel Servet · Sites in Spain
Ages 18–75
Fundación de investigación HM · Sites in Spain
Ages 3–12
University of Seville · Sites in Spain
Ages 18+ · Women only · Healthy volunteers
University of Seville · Sites in Spain
Ages 18+ · Healthy volunteers
Universidad de Córdoba · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 947 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 455 (48%) stop at 75 or younger; 233 take children under 18; 319 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 9 · Phase 4 3
First in 2001; this study’s year is marked. 20 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.
Median enrollment 100 across the 198 interventional studies, 175 across the 32 observational. Of the 127 that completed or were terminated, 2 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 230 have an industry lead sponsor. The 10 most frequent:
Instituto de Investigación Sanitaria Aragón is the lead sponsor of 32 studies on the registry; 12 are open to participants now.
Instituto de Investigación Sanitaria Aragón has 8 studies filed under Anxiety Disorders — fewer than ten, so there is no comparison to draw.
17 of the studies in Anxiety Disorders with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07925723Universidad Miguel Hernandez de ElcheALAS PROPIAS: Music Therapy for Women Experiencing Machista Violence in Intimate Partner Relationships | 2026-11-30 |
| NCT07698379Hospital Miguel ServetPrevention of Burnout in Spanish Healthcare Professionals Through Attachment-Based Compassion Therapy (ABCT) | 2026-11-30 |
| NCT07292610University of Castilla-La ManchaImpact of Nut Consumption on Mental Health in Young Adults | 2026-12 |
| NCT05289258Universidad de CórdobaUnified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments | 2026-12-30 |
| NCT07070531Instituto de Investigación Sanitaria AragónUnified Protocol in Penitentiary Facilities | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 230 studies in Anxiety Disorders with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this project is to contribute to the improvement of psychological care received in primary care (PC), through the study of the cost-effectiveness and acceptability of the Unified Protocol for the treatment of emotional disorders in brief groups in primary care services in Spain (PU-AP) for the treatment of emotional disorders (EDs), the most prevalent in our society. To do so, a pilot study will be carried out, and, subsequently, a randomized clinical trial to study the efficacy, cost-effectiveness and acceptability of the Unified Protocol for the transdiagnostic treatment of EDs, applied in 5 or 8 group sessions. Finally, the researchers will analyze whether there are specific patient profiles that will benefit more from one or the other condition. The results will contribute to the personalization of the psychological treatment of users with EDs attending PC in the Spanish public health system.
Emotional disorders (EDs;including anxiety disorders, unipolar mood disorders, and related disorders) are the most prevalent mental disorders in the general population. In Spain, anxiety disorders and mood disorders affect approximately two million (4.1%) and two and half million (5.2%) individuals, respectively. As a result of their prevalence in the society, EDs have become an alarming health problem due to their associate costs. These disorders have a direct cost of 22.000 million euros (500 euros per capita and year). The total expense of these disorders entails 2.2% of the Gross Domestic Product in Spain.
In recent years, several alternatives have been proposed to address this situation, one of them being an increase in the number of clinical psychologists in our national health system (NHS) and, especially, their incorporation into primary care (PC) services.
It is considered that the incorporation of psychology in PC will help to reduce referral to specialized care because it will be possible to carry out a more exhaustive screening and determine which cases do not require psychological treatment, which cases should be referred to other health care resources and which cases can be treated in PC, usually mild-moderate TE. Another alternative to mitigate the excessive demand for care, regardless of the level of care, is the use of group psychological interventions, a cost-effective format for systems with limited resources such as our NHS.
Transdiagnostic interventions, like the Unified Protocol for the Treatment of EDs (UP), in brief group format, has emerged as a viable option for treating EDs in PC services.
The aim of the present study is to analyze the cost-effectiveness and acceptability of the Unified Protocol for the transdiagnostic treatment of EDs, applied in 5 or 8 group sessions.
Furthermore, it will try to find out which characteristics of the participants (e.g., gender, clinical diagnoses, transdiagnostic dimensions affected, symptom severity) predict a better outcome (e.g., clinical improvement and quality of life) as a function of the sessions received. Thus, in the future, it will be possible to offer the optimal number of sessions according to specific profiles (personalization of treatments).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In both conditions, the contents of the UP manual were worked following the 2nd edition of the UP manual (Barlow et al., 2018). In the 5-session version, Module 1 (Motivation for Change and Commitment to Treatment) was removed, and Modules 6 and 7 (Interoceptive and Emotional Exposure) were combined. The content of Module 8 (Achievement, Maintenance, and Relapse Prevention) was addressed during the follow-up session. The sessions were conducted in groups, lasted 2 hours each, and were held weekly.
Behavioral: 5-session UP condition
In both conditions, the contents of the UP manual were worked following the 2nd edition of the UP manual (Barlow et al., 2018). In the 8-session UP condition, each of the original 8 treatment modules was covered weekly. Module 7 (Emotional Exposure) was delivered across two sessions. The content of Module 8 (Achievement, Maintenance, and Relapse Prevention) was addressed during the follow-up session. The sessions were conducted in groups, lasted 2 hours each, and were held weekly.
Behavioral: 8-session UP condition
Unified Protocol (UP) for transdiagnostic treatment of EDs in 5-session
Unified Protocol (UP) for transdiagnostic treatment of EDs in 8-session
Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS-V)
Diagnostic interview Diagnostic interview
Time frame: Enrollment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Patient Health Questionnaire-9 (PHQ-9)
The PHQ-9 (Patient Health Questionnaire-9) assesses depressive symptoms over the past two weeks using a 9-item scale. Each item is scored from 0 to 3, where 0 = "Not at all" and 3 = "Nearly every day". The total score range is 0-27, and is obtained by summing all item scores. Higher scores indicate more severe depressive symptoms.
Time frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Overall Depression Severity and Impairment Scale (ODSIS)
Consist of five items that evaluate the frequency and the intensity of depressive symptoms and their interference with the person's work or school life and social life. The total score range from 0 to 20 and responses use a 5-point Likert scale ranging from 0 to 4.
Time frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Generalized Anxiety Disorder (GAD-7)
The GAD-7 questionnaire assesses the presence of Generalized Anxiety Disorder (GAD), as listed in the DSM-V. The scale is composed by 7 items. Scores for all 7 items range from 0 (Not at all) and 3 (Nearly every day). Therefore, the total score ranges from 0 and 21. The total score may be categorized into four severity groups: minimal (0-4), mild (5-9), moderate (10-14) and serious (14-20)
Time frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Overall Anxiety Severity and Impairment Scale (OASIS)
The scale presents five items. These items are related with the frequency and intensity of anxiety symptoms and their interference with the person's work or school life and with social life. All items are rated on a 5-point Likert scale ranging from 0 (I didn't feel anxious) to 4 (Constant anxiety).
Time frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
The World Health Organization-Five Well-Being Index (WHO-5)
Is a self-report instrument measuring mental well-being. It consists of five statements relating to the past two weeks. Each statement is rated on a 6-point scale, with higher scores indicating better mental well-being.
Time frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Difficulties in Emotion Regulation Scale (DERS)
Consists of 36-item of six facets of emotion regulation. Items are rated on a scale of 1 ("almost never \[0-10%\]") to 5 ("almost always \[91-100%\]"). Higher scores indicate more difficulty in emotion regulation
Time frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
The Multidimensional Emotional Disorder Inventory (MEDI)
A self-report measure that includes only 49 items and enables to quickly assess the main transdiagnostic dimensions of Emotional disorders: neurotic temperament (MEDI\_NT), positive temperament (MEDI\_PT), depressed mood (MEDI\_DM), autonomic arousal (MEDI\_AA), somatic anxiety (MEDI\_SOM), intrusive cognitions (MEDI\_IC), social concerns (MEDI\_SOC), traumatic re-experiencing (MEDI\_TRM), and avoidance (MEDI\_AVD). It uses a 9-point Likert-type response scale (0 = Does not characterize me; 8 = Totally characterizes me).
Time frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Working Alliance Inventory-Short (WAI-S)
Evaluate the therapeutic or working alliance through 12 items grouped in three dimensions, called task (1, 2, 10 and 12), links (3, 5, 7 and 9) and objectives (4, 6, 8 and 11) measured through a Likert-type scale with scores ranging from 1 = Never to 7 = Always.
Time frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Maladjustment Scale (MI)
Evaluates interference in different vital areas through six items with a 6-point Likert-type response scale (0 = Not at all; 5 = Extremely).
Time frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Adaptation of Client Satisfaction Questionnaire [CSQ-8]
An adaptation of 13 items that measures quality of the intervention and its components, discomfort experienced during treatment through the following 7 questions with a 4-point Likert-type response scale (0 = nothing; 3 =very much): 1) How would you rate the quality of the treatment program you received?; 2) Did you find the kind of psychological intervention you were looking for?; 3) If a friend or family member needed similar help, would you recommend our treatment program?; 4) Has the content you have learned helped you cope more effectively with your problems?; 5) Overall, how satisfied are you with the treatment program you received?; 6) To what extent has this treatment program caused you discomfort?; 7) If you had to seek help again, would you choose a group treatment program?
Time frame: At the end of treatment (approximately 5 or 8 weeks after enrollment), and 1-, 3-, and 6-month follow-ups after treatment completion.
Group Climate Questionnaire (GCQ-S)
The GCQ-S (Group Climate Questionnaire - Short) is a 12-item self-report measuring perceptions of the group's therapeutic environment, with each item rated 0-6 (total score 72). It has three subscales: Engagement (positive group atmosphere; higher scores = greater involvement), Conflict (tension and anger; higher scores = more interpersonal conflict), and Avoidance (withdrawal or evasion of responsibility; higher scores = more disengagement).
Time frame: During treatment (2nd session)
Quality-adjusted Life Years (QALYs)
Measure of disease burden, including both the quality and the quantity of life lived. It is used in economic evaluation to assess the value of medical interventions.
Time frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Work and Social Adjustment Scale (WSAS)
The Work and Social Adjustment Scale (WSAS) identifies problems that affect an individual's ability to carry out everyday tasks. It consists of 5 items, each rated on a scale from 0 (Not at all) to 8 (Very severely). The total score is obtained by summing the ratings for all items, with a maximum possible score of 40. A WSAS score above 20 typically indicates moderately severe or worse psychopathology, while scores between 10 and 20 are associated with significant functional impairment but less severe clinical symptoms.
Time frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Client Service Receipt Inventory (CSRI)
The Client Service Receipt Inventory (CSRI) is a self-report questionnaire that collects information on service use, including health and social care, medication, and other support services. The number of items varies depending on the version and study context, but it typically includes around 50-60 items. It is designed to evaluate the type, frequency, and duration of services used by clients, which can be used to estimate the associated costs and resource utilization.
Time frame: Pre-treatment, post-treatment (5 or 8 weeks after intervention onset), and 1-, 3-, and 6-month follow-ups after treatment completion.
Plan to share: No — Under request
Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.
Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 15 months is above that.
Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start May 2025 → Feb 2026 and primary completion Sep 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto de Investigación Sanitaria Aragón